CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Q3 FY2024 earnings call

• Restructuring initiatives to manage cost structure, with over 6% reduction in total headcount since late 2023, and ongoing footprint optimization to consolidate sites, expected to generate $40M annualized net savings by 2026.
• Commercial enhancements to focus on client-centric approach, leveraging technology like Apollo platform and RMS e-commerce initiatives.
• Evaluating additional strategies to drive efficiency, including leveraging technology and global business service model to streamline processes and generate procurement savings.
• Record free cash flow of over $200M in Q3 2024, with plans for stock repurchases and debt repayment to protect shareholder value.

DSA segment: Revenue was $615.1 million in the third quarter, a decrease of 7.4% on an organic basis. DSA operating margin was 27.4% in the third quarter, a 20 basis point increase from the third quarter of 2023 and a 30 basis point increase sequentially. RMS segment: Revenue was $197.8 million, an increase of 0.6% on an organic basis over the third quarter of 2023. RMS operating margin increased by 210 basis points to 21% in the third quarter. Manufacturing Solutions segment: Revenue was $196.9 million, an increase of 11.8% on an organic basis compared to the third quarter of last year. Manufacturing segment’s third quarter operating margin was 28.7%, representing an increase of 420 basis points year-over-year.

• Narrowed and slightly raised full year guidance: organic revenue decline 3%-4%, non-GAAP EPS $10.10-$10.30.
• Expect current trends to persist into 2025, pressuring year-over-year growth rates, especially in DSA segment due to pricing environment and global biopharma demand step-down anniversary.
• Fourth quarter outlook: revenue decline low- to mid-single-digit on reported and organic basis; non-GAAP EPS $2.45-$2.65.

• Biopharmaceutical demand environment remains challenging with organic revenue decline. Funding environment and interest rate sentiment pose puts and takes on outlook. Global biopharmaceutical clients' ongoing restructuring programs and slow biotech growth recovery present risks. Pricing pressures in DSA segment and potential margin pressure due to cost actions and pricing dynamics.

Q: Please walk through the puts and takes in terms of funding environment and interest rates and any change in view post-election?

A: Flavia Pease mentioned macroeconomic and funding environment with IPO market support, interest rates coming down, and biotech demand indicators favorable vs last year but at a slower clip. James Foster noted uncertainty on election impact but expected less focus on drug prices with new administration.

Q: How much benefit from lower incentive comp in the quarter?

A: Flavia Pease stated it did not have a meaningful impact in Q3, with the big adjustment in 2Q.